Harding et al. noted that in the ten out of twenty-seven HCC patients with either Barcelona Clinic Liver Cancer (BCLC) Stages B or C treated with immunotherapy, seven had the CTNNB1 mutation while three had another mutation leading to an active Wnt pathway. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.